Skip to main content

Table 5 Uni- and multivariate analyses for progression-free survival (PFS)

From: Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome

 

Events/Patients

Median PFS(months)

P 1

HR2

95% CI3

P 4

Covariate

      

Age (≤70 vs >70 years)

32/36 vs 11/13

17.0 vs 18.0

0.50

0.61

0.30-1.20

0.15

Sex (male vs female)

24/28 vs 19/21

18.3 vs 15.6

0.73

1.28

0.69-2.35

0.42

Grading (G1/G2 vs G3)

15/20 vs 28/29

17.3 vs 13.3

0.007

1.83

1.01-3.31

0.04

Response to 1st-line CT0 (CR vs PR vs SD vs PD)

7/8 vs 18/23 vs 12/12 vs 6/6

20.1 vs 20.0 vs 9.8 vs 7.6

0.0026

1.86

1.32-2.62

0.0004

FcγRIIIa (VV vs VF vs FF)

13/18 vs 25/26 vs 5/5

18.2 vs 17.3 vs 9.4

0.04

2.35

1.37-4.01

0.001

FcγRIIa (HH vs HR vs RR)

17/18 vs 23/27vs 3/4

16.1 vs 18.2 vs 13.3

0.61

1.19

0.72-1.96

0.49

  1. P1 = Log Rank P.
  2. HR2 = Cox regression HR.
  3. CI3 = Confidence Intervals.
  4. P4 = Cox’s Proportional Hazards Regression P.